Core Viewpoint - The China Securities Index for the medical industry has shown a decline in performance over various time frames, indicating potential challenges within the sector [2]. Group 1: Index Performance - The China Securities Index for the medical industry has decreased by 5.99% over the past month, 1.12% over the past three months, and 6.26% year-to-date [2]. - The index was established with a base date of December 31, 2021, set at 1000.0 points [2]. Group 2: Index Composition - The top ten weighted companies in the index include: - Mindray Medical (14.15%) - Aier Eye Hospital (9.35%) - United Imaging (8.03%) - Aimeike (4.1%) - Huatai Medical (3.87%) - New Industry (3.16%) - Shanghai Pharmaceuticals (3.11%) - Yuyue Medical (3.06%) - Yifeng Pharmacy (2.49%) - Meinian Onehealth (2.45%) [2]. - The index's holdings are primarily listed on the Shenzhen Stock Exchange (56.76%) and the Shanghai Stock Exchange (43.24%) [2]. Group 3: Sector Allocation - The sector allocation within the index is as follows: - Medical Devices: 34.77% - Medical Consumables: 22.92% - Pharmaceutical Commerce: 15.73% - Medical Services: 14.44% - In Vitro Diagnostics: 12.14% [2]. Group 4: Sample Adjustment - The index samples are adjusted biannually, with adjustments occurring on the next trading day following the second Friday of June and December [3]. - Weight factors are generally fixed until the next scheduled adjustment, with temporary adjustments made in response to significant events affecting sample companies [3].

Investment Rating - The report maintains a "Buy" rating for the company, with a target price not specified [6][17]. Core Views - The company experienced a revenue decline of 17.90% year-over-year in Q1 2025, with total revenue of 663 million yuan and a net profit of 444 million yuan, down 15.87% year-over-year [1]. - The gross margin remained stable at 93.85%, with a slight decrease of 0.70 percentage points year-over-year, while the net profit margin increased by 1.61 percentage points to 66.88% [2]. - The company is pursuing growth through acquisitions and international expansion, notably a planned acquisition of a Korean company for 190 million USD, which is expected to enhance its sales capabilities and open up overseas markets [3]. - The company has a robust pipeline of internal R&D projects, with 11 Class III medical device products already available, and several others in various stages of development, which is expected to support a return to growth [4]. Financial Summary - The company forecasts revenues of 3.29 billion yuan, 3.71 billion yuan, and 4.22 billion yuan for 2025, 2026, and 2027 respectively, with net profits projected at 2.13 billion yuan, 2.40 billion yuan, and 2.73 billion yuan for the same years [4][10]. - The company’s financial metrics indicate a PE ratio of 25x for 2025, decreasing to 20x by 2027, reflecting an expected improvement in profitability [4][10].

邮箱：xuyl@csco.com.cn 公司具备证券投资咨询业务资格 证券研究报告 医药生物 G 国产创新药闪耀 ASCO [Table_ReportType] 医药生物行业周报（4 月第 4 周） [Table_S 行业ummary 观点：] 请务必阅读文后重要声明及免责条款 [Table_ReportDate] 2025 年 04 月 28 日 [Table_Author] 分析师：王俐媛 执业证书号：S1030524080001 电话：0755-83199599 邮箱：wangly1@csco.com.cn 研究助理：徐伊琳 电话：0755-23602217 [Table_Industry] [Table_BaseData] 1) 周度回顾。上周（4 月 21 日-4 月 25 日）医药生物收 涨 1.16%，跑赢 wind 全 A（1.15%）和沪深 300（0.38%）。 从板块来看，医疗研发外包（6.34%）和原料药（4.72%） 部分个股一季报表现亮眼，涨幅居前，血液制品（- 3.26%）和疫苗（-6.38%）延续上周跌势。从个股来看， 永安药业（31.4%）、舒泰神（28.4%）和尔康制药（2 ...

21世纪经济报道记者 李佳英 广州报道 与同行业其他企业销售费用策略的横向比较显示，华熙生物或许正陷入营销高投入却回报乏力的困境。 2022年其销售费用高达30.49亿元，远超竞争对手爱美客和昊海生科。尽管公司已经连续两年压缩销售 开支至2024年的24.64亿元，净利润率却仍从2022年的15.1%跌至3.2%，销售效率低下的问题愈发突出。 华熙生物的业绩下滑并非偶然事件，而是多重因素交织的结果。从其发展的纵向脉络来看，华熙生物正 处于"第三次战略升级"的阵痛期，专注于糖生物学和细胞生物学两大新兴领域。 财务报告显示，这一转型伴随着管理成本的显著增加——从2022年至2024年，管理费用从3.93亿元增至 6.58亿元，管理费用率也从6.18%上升至12.26%。 2025年首季度，医美行业内的"三剑客"交出的成绩单，却是一串令人瞩目的下滑数字。 根据4月25日至26日公布的财务报告，华熙生物一季度营业收入同比下跌20.77%，缩水至10.78亿元；爱 美客（300896）的收入亦下降17.90%，降至6.63亿元；昊海生科的营收亦减少4.25%，徘徊在6.19亿 元。这一系列下滑的数据，暴露出传统医美企业 ...

点击注册小程序 查看完整报告 特别申明： 本订阅号中所涉及的证券研究信息由光大证券研究所编写，仅面向光大证券专业投资者客户，用作新媒体形势下研究 信息和研究观点的沟通交流。非光大证券专业投资者客户，请勿订阅、接收或使用本订阅号中的任何信息。本订阅号 难以设置访问权限，若给您造成不便，敬请谅解。光大证券研究所不会因关注、收到或阅读本订阅号推送内容而视相 关人员为光大证券的客户。 报告摘要 事件： 公司发布2025年一季报，1Q2025营业收入为6.6亿元，同比下滑17.9%，归母净利润为4.4亿元，同比下滑 15.9%。 点评： 高基数+产品结构分化，一季度业绩有所下滑 我们认为，公司一季度收入同比下滑主要原因系：第一，去年同期基数较高；第二，产品销售结构性分 化，溶液类产品整体出货价格走低。 产品结构性分化，一季度毛利率略有下滑 1Q2025，公司毛利率为93.9%，同比-0.7pcts；归母净利率为66.9%，同比+1.6pcts。我们认为，公司一季 度毛利率同比微降也是受产品出货结构的影响。 1Q2025公司期间费用率同比+4.1pcts至21.9%。分项目看，销售/管理/研发/财务费用率分别为 9.9% ...

Investment Rating - The report maintains a "Buy" rating for the company [5][15]. Core Views - The company's Q1 2025 performance showed a decline in revenue and net profit due to a high base from the previous year and a structural differentiation in product sales, particularly a decrease in the overall selling price of solution products [1][2]. - The gross margin slightly decreased to 93.9%, down by 0.7 percentage points year-on-year, while the net profit margin increased to 66.9%, up by 1.6 percentage points year-on-year [2]. - The company is expected to achieve long-term growth through overseas expansion and strengthening its new product lineup, with the acquisition of REGEN Biotech, Inc. enhancing its regenerative product system and facilitating international market entry [3]. Financial Performance Summary - Q1 2025 revenue was 660 million yuan, a year-on-year decrease of 17.9%, and net profit was 440 million yuan, down 15.9% year-on-year [1]. - The company’s operating expenses increased by 4.1 percentage points year-on-year to 21.9% [2]. - Other income rose significantly by 559.6% year-on-year to 21.71 million yuan, mainly due to increased government subsidies [2]. Earnings Forecast and Valuation - Revenue and net profit forecasts for 2025-2027 are maintained, with expected EPS of 6.84, 8.10, and 9.30 yuan respectively, corresponding to P/E ratios of 25, 21, and 19 times [3][4]. - The company is projected to achieve revenue of 3.213 billion yuan in 2025, with a growth rate of 6.18% [4]. - The net profit for 2025 is estimated at 2.071 billion yuan, reflecting a growth rate of 5.77% [4]. Profitability and Financial Ratios - The gross margin is projected to be 94.2% in 2025, with a slight decrease from previous years [13]. - The return on equity (ROE) is expected to decline gradually from 29.28% in 2023 to 22.29% in 2027 [13]. - The company maintains a strong liquidity position, with a current ratio projected at 26.22 in 2025 [13].

Investment Rating - The investment rating for the company is "Outperform the Market" [2][4][9]. Core Views - The company's overall performance in Q1 2025 faced pressure, with revenue of 664 million yuan, down 17.9% year-on-year, and net profit attributable to shareholders of 444 million yuan, down 15.87% year-on-year. The decline is attributed to the overall pressure on the aesthetic medicine terminal market, but future overseas acquisitions are expected to open new growth opportunities [1][5]. - The company announced plans to acquire 59.5% of Korean REGEN Biotech to strengthen its regenerative aesthetic product layout and leverage the acquisition to expand international market sales [1][5]. - The gross profit margin slightly decreased to 93.85%, down 0.7 percentage points year-on-year, influenced by changes in product structure. R&D investment intensity has increased, with R&D expense ratio at 8.82%, up 1.7 percentage points year-on-year [1][7]. Financial Performance and Forecast - The company forecasts revenue growth from 2,869.35 million yuan in 2023 to 4,377.70 million yuan in 2027, with a compound annual growth rate (CAGR) of approximately 13.74% [3]. - Net profit is projected to grow from 1,858.48 million yuan in 2023 to 2,802.90 million yuan in 2027, reflecting a CAGR of about 15.34% [3]. - The earnings per share (EPS) is expected to increase from 8.59 yuan in 2023 to 9.28 yuan in 2027 [3]. - The company has adjusted its net profit forecasts for 2025-2027 to 2,123 million yuan, 2,430 million yuan, and 2,803 million yuan, respectively, with corresponding price-to-earnings (PE) ratios of 24.6, 21.5, and 18.6 [2][9].

Investment Rating - The investment rating for the company is "Outperform the Market" [2][4][9]. Core Views - The company's overall performance in Q1 2025 faced pressure, with revenue of 664 million yuan, down 17.9% year-on-year, and net profit attributable to shareholders of 444 million yuan, down 15.87% year-on-year. The decline is attributed to the overall pressure on the medical beauty terminal market, but future overseas acquisitions are expected to open new growth opportunities [1][5]. - The company announced plans to acquire 59.5% of Korean REGEN Biotech to strengthen its regenerative medical product layout and leverage the acquisition to expand international market sales [1][5]. - The gross profit margin slightly decreased to 93.85%, down 0.7 percentage points year-on-year, influenced by changes in product structure. R&D investment intensity has increased, with R&D expense ratio at 8.82%, up 1.7 percentage points year-on-year [1][7]. Financial Forecasts and Metrics - Revenue projections for 2025-2027 have been revised down to 21.23 billion yuan, 24.3 billion yuan, and 28.03 billion yuan, respectively, with corresponding P/E ratios of 24.6, 21.5, and 18.6 [2][9]. - The company is expected to see revenue growth of 12.33% in 2025, 13.24% in 2026, and 13.74% in 2027, with net profit growth rates of 8.44%, 14.48%, and 15.34% for the same years [3][11]. - The projected earnings per share (EPS) for 2025 is 7.03 yuan, with a net profit margin of 70.74% [3][11].

Core Viewpoint - Aimeike Technology Development Co., Ltd. reported a decline in revenue and net profit for Q1 2025, indicating challenges in the medical aesthetics industry amid increased competition and regulatory pressures [1][2]. Financial Performance - In Q1 2025, Aimeike achieved revenue of 663 million yuan, a year-on-year decrease of 17.90% - The net profit attributable to shareholders was 444 million yuan, down 15.87% year-on-year [1]. Market Trends - The non-surgical light medical aesthetics market is expected to grow at a rate of 10% in 2024, down from previous highs in 2023, as the industry transitions from "technical dividends" to "comprehensive competitiveness" [2]. - Increased competition has led to a downward trend in product prices, while consumer decision-making periods for high-end medical aesthetics have lengthened due to macroeconomic uncertainties [2]. Strategic Positioning - Aimeike is one of the few leading companies not actively participating in price wars, maintaining a gross margin of 93.85% in Q1 2025, a slight decrease of 0.7 percentage points year-on-year [4]. - The company emphasizes brand value and product quality over short-term price advantages, aiming for long-term market resilience [4]. Research and Development - Aimeike's R&D expenses reached 58.54 million yuan in Q1 2025, accounting for 8.82% of revenue, an increase of 1.65% year-on-year, reflecting a strong commitment to innovation [4]. - Ongoing projects focus on cutting-edge areas such as regenerative materials and collagen, which may not yield immediate sales but are expected to drive long-term growth [4]. Product Expansion - Aimeike has received approval for a new product, a medical-grade gel for jawline filling, which will soon be launched, marking it as the third approved product in this category in China [5]. - The company is also expanding its market presence through the acquisition of 85% of South Korea's REGEN Biotech Inc. for approximately 190 million USD, positioning itself as the only domestic company with two regenerative medical aesthetics products [5].

盘中原油曾涨超1%，黄金一度涨超2%。 亚洲时段，沪指冲高回落微涨0.03%，工农中三大行股价创新高，恒科指跌超1%，生物医药股逆势走强，国债期货全线下跌。 华见早安之声 请各位听众升级为见闻最新版APP，以便成功收听以下音频。 市场概述 沃勒等美联储高官讲话令市场的降息预期升温，美国股债齐涨，金油反弹。 纳指涨近3%。特斯拉、英伟达、微软、亚马逊均收涨超3%。财报后，下调指引的宝洁跌近4%，谷歌盘后跳涨超5%。中概指数盘初跌1.5%后转涨，录得四 连阳。 美联储官员讲话后，美债收益率加速下行。两年期美债收益率和美元指数脱离一周高位。离岸人民币盘中跌近200点失守7.30。比特币走V形。 付鹏说|最新更新，重新理解欧洲系列 ,了解详情>> 要闻 外交部：中美没有就关税问题磋商或谈判，更谈不上达成协议。央视网：特朗普考虑对华关税分级方案。 美联储当红理事沃勒：就业市场若严重下滑，可能令美联储更多、更快降息。美联储高官Hammack：有了清晰、令人信服的数据后，可能6月采 取行动。 日本财相称与美国确认市场决定汇率，日本据称考虑增加购买美国大豆。美财长料下周美韩达成贸易谅解协议，韩国ETF刷新日高。德国财长 称， ...